Previous Close | 173.85 |
Open | 173.85 |
Bid | 150.00 x 1400 |
Ask | 171.95 x 900 |
Day's Range | 169.85 - 174.51 |
52 Week Range | 169.85 - 242.97 |
Volume | |
Avg. Volume | 572,777 |
Market Cap | 21.444B |
Beta (5Y Monthly) | 0.45 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.56 |
Earnings Date | Oct 25, 2023 - Oct 30, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 247.55 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALNY
In this article, we will be taking a look at the 13 best beaten down stocks to buy now. To skip our detailed analysis of the US stock market and recent developments within it, you can go directly to see the 5 Best Beaten Down Stocks To Buy Now. The Two-Day Fed Meeting On September […]
Alnylam stock tumbled Thursday after a split advisory panel recommended the Food and Drug Administration approve its heart disease treatment.
Alnylam (ALNY) receives a positive opinion from the FDA's advisory committee regarding the label expansion of patisiran to treat the cardiomyopathy of transthyretin-mediated amyloidosis.